12 June 2017
Saniona AB (publ) (“Saniona” or the “Company”) has prepared a prospectus regarding the admission to trading of the Company’s shares on Nasdaq Stockholm. Last day of trading on Nasdaq First North Premier is June 14, 2017 and the first day of trading on Nasdaq Stockholm is planned for June 15, 2017.
The prospectus has today, 12 June 2017, approved and registered by the Swedish financial supervisory authority and is now available on the Company’s website (www.saniona.se) and Pareto Securities website (www.paretosec.se).
Pareto Securities AB has been the financial advisor and Setterwalls Advokatbyrå AB has served as legal advisor in connection with the listing.
For more information, please contact:
Thomas Feldthus, executive vice president and CFO, Saniona. Mobile: +45 2210 9957, E-mail: email@example.com
The information was submitted, by the above contact person in the government, for publication on 12 June 2017, there is a 12:15 CET.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and pain management. The company has an extensive portfolio of potential drug candidates in preclinical or clinical Phase. The research is focused on the ion channels that constitute a unique class that allows for and controls the passage of ions in cell membranes. The company has partnered with Boehringer Ingelheim GmbH. Proximagen Ltd., Productos the medix, S. A de S. V and Luc Therapeutics. Saniona is based in Copenhagen where the company has a forskningssite of high international class. Saniona is listed on Nasdaq First North Premier and has approximately 5,000 shareholders. Pareto Securities is the Certified Adviser of Saniona. The share is traded under the ticker SANION. Read more at www.saniona.com.
20170612 – PR – Prospectus – ENG